Brain Injury Advocates Team Up to “Tackle TBI” in New Public Service Announcement

Helius Medical Technologies, Brain Injury Association of America,
Former NFL Player Marvin Washington and Montel Williams Raise Awareness
for Traumatic Brain Injury and Concussion

NEWTOWN, Pa.–(BUSINESS WIRE)–Helius Medical Technologies (TSX:HSM, OTCQB:HSDT) (“Helius” or the
“Company”) 
in partnership with the Brain Injury Association of
America, has launched Tackling
TBI
,” a new Public Service Announcement (PSA) featuring
patient and veteran advocate Montel Williams and former NFL player
Marvin Washington. The PSA is designed to raise awareness of Traumatic
Brain Injury (TBI) and concussions as growing health issues and to
provide patients with education, resources and encouragement to
participate in clinical trials to support development of new therapies.
Information on a Helius sponsored clinical trial for TBI can be found at www.braininjurytrial.com.


“Currently more than 5.3 million Americans in the U.S. live with a
lifelong disability as a result of a TBI and there are 1.7 million new
cases each year,” said Montel Williams. “Our goal is to ensure that the
public at large understands the problem and that patients and caregivers
understand where to go for resources that can help.”

The PSA featuring Williams and Washington reminds viewers that a TBI can
range from subtle to severe, symptoms can take years to progress and
that it’s important to speak with a doctor or healthcare professional if
they think they’ve had a brain injury. To view the PSA, visit www.tacklingtbi.com.

“We are proud to partner on the launch of this PSA initiative to raise
awareness and understanding of brain injury,” said Susan Connors,
president and chief executive officer of the Brain Injury Association of
America (BIAA). “A diagnosis of TBI can be the start of a misdiagnosed
and misunderstood neurological disease. We need to continue to provide
help, hope and healing for the millions of Americans who sustain this
life-altering, sometimes devastating, injury.”

A TBI is an injury that disrupts the normal function of the brain and
can be caused by a host of things such as sports, car accidents,
military service, trips, slips or falls. For many people, TBI causes
fatigue, headaches, and difficulty with balance or motor skills, slurred
speech, or seizures.

About the Brain Injury Association of American (BIAA)

The Brain Injury Association of America is the country’s oldest and
largest nationwide brain injury advocacy organization. Our mission is to
advance awareness, research, treatment, and education and to improve the
quality of life for all people affected by brain injury. BIAA is
dedicated to increasing access to quality health care and raising
awareness and understanding of brain injury. Further resources and
information related to brain injury are available at http://www.BIAUSA.org,
BIAA on Facebook and Twitter Page and through the National Brain Injury
Information Center (NBIIC) at 1-800-444-6443.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on
neurological wellness. Helius seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain’s
ability to heal itself. For more information, please visit www.heliusmedical.com.

To download the “Tackling TBI” PSA and for media resources visit: www.tacklingtbi.com.

The Toronto Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical
facts and constitute forward-looking statements or forward-looking
information within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws (“forward-looking
statements”).

All statements other than statements of historical fact included in this
news release are forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include, among others,
statements regarding ongoing or planned clinical research, expected
future development timelines, regulatory approvals, business initiatives
and objectives and use of proceeds from financings or other business
initiatives.

Forward-looking statements are often identified by terms such as “will”,
“may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate
and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure of the Company to achieve its business objectives
and other risks detailed from time to time in the filings made by the
Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any
forward-looking statements may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control
of the Company. The reader is cautioned not to place undue reliance on
any forward-looking statement. Such information, although considered
reasonable by management at the time of preparation, may prove to be
incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news release
are expressly qualified by this cautionary statement. Risks and
uncertainties about the Company’s business are more fully discussed in
the Company’s disclosure materials, including the short form prospectus
filed in connection with the Offering, its Annual Report on Form 10-K
filed with the United States Securities and Exchange Commission and the
Canadian securities regulators and which can be obtained from either at www.sec.gov
or www.sedar.com.

Contacts

Helius Medical Technologies, Inc.
Becky Kern, 914-772-2310
bkern@heliusmedical.com